title: Chromatographic behaviour predicts the ability of potential nootropics to permeate the blood-brain barrier.
abstract: The log BB parameter is the logarithm of the ratio of a compound's equilibrium concentrations in the brain tissue versus the blood plasma. This parameter is a useful descriptor in assessing the ability of a compound to permeate the blood-brain barrier. The aim of this study was to develop a Hansch-type linear regression QSAR model that correlates the parameter log BB and the retention time of drugs and other organic compounds on a reversed-phase HPLC containing an embedded amide moiety. The retention time was expressed by the capacity factor log k'. The second aim was to estimate the brain's absorption of 2-(azacycloalkyl)acetamidophenoxyacetic acids, which are analogues of piracetam, nefiracetam, and meclofenoxate. Notably, these acids may be novel nootropics. Two simple regression models that relate log BB and log k' were developed from an assay performed using a reversed-phase HPLC that contained an embedded amide moiety. Both the quadratic and linear models yielded statistical parameters comparable to previously published models of log BB dependence on various structural characteristics. The models predict that four members of the substituted phenoxyacetic acid series have a strong chance of permeating the barrier and being absorbed in the brain. The results of this study show that a reversed-phase HPLC system containing an embedded amide moiety is a functional in vitro surrogate of the blood-brain barrier. These results suggest that racetam-type nootropic drugs containing a carboxylic moiety could be more poorly absorbed than analogues devoid of the carboxyl group, especially if the compounds penetrate the barrier by a simple diffusion mechanism.
authors: Institute of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, 612 42, Brno, Czech Republic.
authors: Oldřich
authors: O
authors: Farsa
keywords: Blood-brain barrier; Embedded amide moiety; Hansch analysis; Nootropics; RP-HPLC
references: Adv Drug Deliv Rev. 2002 Mar 31;54(3):291-313
references: 11922949
references: Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S29-39
references: 11033425
references: Drugs. 2010 Feb 12;70(3):287-312
references: 20166767
references: Brain Res Brain Res Rev. 1994 May;19(2):180-222
references: 8061686
references: J Chem Inf Comput Sci. 2002 May-Jun;42(3):651-66
references: 12086527
references: J Med Chem. 1988 Mar;31(3):656-71
references: 2894467
references: Eur J Med Chem. 2001 Sep;36(9):719-30
references: 11672881
references: J Med Chem. 1996 Nov 22;39(24):4750-5
references: 8941388
references: J Pharm Sci. 1998 Aug;87(8):952-9
references: 9687339
references: NeuroRx. 2005 Jan;2(1):54-62
references: 15717057